<DOC>
	<DOCNO>NCT02884297</DOCNO>
	<brief_summary>The purpose study evaluate feasibility measurement placental perfusion first trim pregnancy 3D Doppler ultrasound angiography contrast agent : SonoVue® .</brief_summary>
	<brief_title>HexafluOride , Contrast Agent Placenta Echo-angiography</brief_title>
	<detailed_description>The quality utero-placental vascularization major point foetal healthy development healthy pregnancy . Pre-eclampsia ( PE ) Intra-Uterine Growth Retardation ( IUGR ) currently two major pregnancy complication West . Those placental pathology cause 30 per cent foetal maternal morbidity-mortality . The relationship pathology , affect 4 7 per cent pregnancy , chronic utero-placental hypoperfusion , cause failure implantation first trim pregnancy , confirm . A hypoxic environment surround embryonic implantation first step placental development uterus . Moreover , maternal-foetal exchange space ( Inter-Villi Space IVS ) maternal-bloodless . At pregnancy first period release uterine secretion plasmatic ultra-filtrate . Indeed , end uterine artery plug trophoblastic plug . The accurate time plug disappearance still undetermined , even major step set maternal-foetal interface . It would average 10 week amenorrhea ( 10 SA ) . An over-earlier plug disappearance loss hypoxic environment could entail phenomena chronic placental hypoperfusion notice case PE IUGR . Since 2004 , quantification placental uterine vascularization possible Doppler 3D ultrasound angiography use signal high-correlated perfusion level interest organ . However , Doppler signal represent movement reflective particle , specific blood flow . A signal due movement red blood cell could detect IVS method . Because high sensibility movement lack specificity blood flow , le Doppler 3D signal measure IVS affirm represent perfusion maternal blood . Only injection vascular contrast agent could allow define specific appearance maternal blood , ultra-filtrate , IVS . The use contrast agent may allow study firstly vivo early step development uterine-placental vascularization IVS perfusion maternal blood . SonoVue® contain microbubbles hexafluoride sulphur performs reflector ultrasonic beam average 6 µm diameter like one red blood cell . By improve blood echogenicity signal/noise rate , contrast agent detect IVS space well perfuse maternal blood . No Marketing Authorization ( MA ) pregnant patient exist . It currently use wanted pregnancy , purpose lead study population woman express twice wish voluntary termination pregnancy . Currently , technique allows study appearance kinetic maternal blood IVS describe way . This kinetic would major impact progression pregnancy analysis may permit screen test early diagnosis PE- IUGR-risky pregnancy .</detailed_description>
	<criteria>Age ≥18 year &lt; 65 year , Gestational Age : 8 SA ≤ gestational age ≤ 8 SA + 6 day 12 SA ≤ gestational age ≤ 12 SA + 6 day , BMI ≤30 kg / m² , Having confirm request termination pregnancy surgically 1 . Any medical contraindication administration SonoVue include : Hypersensitivity sulfur hexafluoride component SonoVue® , Women recent acute coronary syndrome suffer unstable ischemic heart disease , woman rightleft shunt , severe pulmonary hypertension ( pulmonary artery pressure &gt; 90 mmHg ) , uncontrolled systemic hypertension woman respiratory distress syndrome 2 . Women risk IUGR / PE namely : Previous history PE stunt staff Autoimmune disease , Chronic Hypertension Diabetes</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>